Myriad Genetics Inc. Aktie

Myriad Genetics will hold its fourth quarter and full year 2024 earnings conference call at 4:30 pm ET on Monday,

Myriad Genetics entered into an agreement with CancerCARE for Life to provide individuals within the latters network with access to

Myriad Genetics launches an online prenatal genetic testing resource, the Know More Sooner website, to provide comprehensive information about reproductive

Myriad Genetics enters into an agreement with Hannah Storm, who will be the Myriad Genetics Breast Cancer Risk Assessment Program

Strategic progress and solid potential in oncology testing keep MYGN on investors radar.

Myriad Genetics announced the election of Mark S. Davis to its Board of Director, effective immediately, expanding the Board from

Myriad Genetics Prolaris test reinforced as an Advanced Tool by the NCCN for prognostic assessment.

Myriad Genetics, Inc. announced it will present new data at the 2024 San Antonio Breast Cancer Symposium.

Myriad Genetics incorporates its proprietary HRD platform in Illuminas updated TruSight Oncology 500 v2 comprehensive gene panel assay.